Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Biochemistry & Molecular Biology
Luca X. Zampieri, Martina Sboarina, Andrea Cacace, Debora Grasso, Leopold Thabault, Loic Hamelin, Thibaut Vazeille, Elodie Dumon, Rodrigue Rossignol, Raphael Frederick, Etienne Sonveaux, Florence Lefranc, Pierre Sonveaux
Summary: The study found that mitochondria in glioblastoma cells become fitter in response to chemotherapy, leading to chemoresistance. By inhibiting oxidative phosphorylation and/or autophagy/mitophagy, this resistance can be targeted. Some PARP inhibitors were also found to be inhibitors of mitochondrial Complex I.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Frank Saran, Liam Welsh, Allan James, Catherine McBain, Rao Gattamaneni, Sarah Jefferies, Fiona Harris, Karine Pemberton, Jennifer Schaible, Shaun Bender, Agnieszka Cseh, Michael Brada
Summary: This study aimed to determine the maximum tolerated dose of afatinib in combination with radiotherapy for patients with GBM. The study identified the maximum tolerated dose as 30 mg when combined with daily TMZ and RT, and 40 mg when combined with RT alone. Further studies on afatinib in GBM patients are recommended, focusing on biomarker-based preselection.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
Yan Zou, Zi'xiang Liu, Yi'nan Zhou, Jing Wang, Qin'yi Xu, Xu'dong Zhao, Zeng'li Miao
Summary: Research has found that TRPC5 and P-gp are upregulated in TMZ-resistant glioblastoma cells, and downregulation of TRPC5 can inhibit P-gp expression and significantly reverse TMZ resistance; TRPC5-siRNA limited the tumor xenograft growth of TMZ-resistant cells in an athymic nude mouse model; in specimens from patients with recurrent glioblastoma, TRPC5 and P-gp are highly expressed.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Cell Biology
Elena Navarro-Carrasco, Pedro A. Lazo
Summary: Depletion of the chromatin kinase VRK1 using RNA interference reduces glioblastoma cell dependence on temozolomide and olaparib, promoting tumor cell death.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Makoto Ohno, Chifumi Kitanaka, Yasuji Miyakita, Shota Tanaka, Yukihiko Sonoda, Kazuhiko Mishima, Eiichi Ishikawa, Masamichi Takahashi, Shunsuke Yanagisawa, Ken Ohashi, Motoo Nagane, Yoshitaka Narita
Summary: Metformin shows potential for treating glioblastoma and phase I study results indicate good tolerance of 2250 mg/day dose, leading to a phase II study to evaluate its clinical benefits.
Article
Oncology
Junhui Liu, Lun Gao, Xiaonan Zhu, Rongxin Geng, Xiang Tao, Haitao Xu, Zhibiao Chen
Summary: The study revealed that GSDMD expression was upregulated in glioma, significantly associated with WHO grade IV, IDH 1/2 wild-type, and mesenchymal subtypes, as well as shorter overall survival. GSDMD may participate in regulating macrophage infiltration and polarization, serving as a prognostic biomarker and TMZ-treatment response marker in glioma.
Article
Multidisciplinary Sciences
Silvia Chiesa, Antonella Mangraviti, Maurizio Martini, Tonia Cenci, Ciro Mazzarella, Simona Gaudino, Serena Bracci, Antonella Martino, Giuseppe M. Della Pepa, Martina Offi, Marco Gessi, Rosellina Russo, Matia Martucci, Francesco Beghella Bartoli, Luigi M. Larocca, Liverana Lauretti, Alessandro Olivi, Roberto Pallini, Mario Balducci, Quintino Giorgio D'Alessandris
Summary: This study aimed to identify molecular predictive factors for response to regorafenib in recurrent IDH-wildtype glioblastoma patients and found that mutations in the MAPK pathway may predict poor response and shorter survival in patients treated with regorafenib.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando
Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Raj Singh, Eric J. Lehrer, Ming Wang, Haley K. Perlow, Nicholas G. Zaorsky, Daniel M. Trifiletti, Joseph Bovi, Pierina Navarria, Silvia Scoccianti, Vinai Gondi, Paul D. Brown, Joshua D. Palmer
Summary: DE-RT alone showed superior PFS and OS compared to SoC-RT alone in patients with glioblastoma multiforme. However, DE-RT + TMZ did not lead to improved outcomes compared to SoC-RT + TMZ, and no differential benefit based on MGMT status was found. Future studies are needed to identify which subgroups benefit most from DE-RT.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Polymer Science
Kang Xu, Long Zhang, Yuqi Gu, Huasha Yang, Baixiang Du, Hongmei Liu, Yuling Li
Summary: The synthesis of PEtOz-TMZ conjugate has shown enhanced efficacy and stability of TMZ in vivo, indicating a promising route of administration for TMZ in clinical practice.
EUROPEAN POLYMER JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Ceyhan Hacioglu, Cengiz Tuncer
Summary: This study demonstrates that boric acid can enhance chemosensitivity in TMZ-resistant GBM cells by modulating the ferritinophagy pathway.
BIOLOGICAL TRACE ELEMENT RESEARCH
(2023)
Article
Oncology
Martin Glas, Matthew T. Ballo, Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf, Suriya Jeyapalan, Terence T. Sio, Paul M. DeRose, Martin Misch, Sophie Taillibert, Zvi Ram, Andreas F. Hottinger, Jacob Easaw, Chae-Yong Kim, Suyash Mohan, Roger Stupp
Summary: TTFields treatment affects the rate of distant progression in newly diagnosed GBM patients, with distant lesions appearing further from the primary lesion in the TTFields treatment arm. Distant progression correlates with improved clinical outcomes in TTFields patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.